EGRX is a low float stock. Traders piled in for their busy December and are now selling after the 3rd and final expected PR IMO. I believe the will use their cash position to in-license new drugs.
Nothing negative in today's PR, IMO. Alcohol-free Docetaxel was never expected to be a big-selling product like Bendeka.
EGRX shares are quite volatile compared to a typical biotech company with a comparable EV. They often move 5% or more in a given day with no news whatsoever.
Market Data 
Markets 
AI
